TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers at the University of Kentucky report that mice with Alzheimer’s-like brain changes slept more than two additional hours per day after most microglia were temporarily depleted. Amyloid plaques were not removed, but the result is from animal experiments and does not show that the approach is safe or effective in people.
Researchers at the University of Kentucky report that mice with Alzheimer’s-like brain changes slept more than two hours longer per day after most of their brain immune cells were temporarily depleted, even though amyloid plaques were not cleared. The findings, published in Alzheimer’s & Dementia, point to microglia and inflammation as possible contributors to sleep disruption, but do not establish a treatment for people with Alzheimer’s.
The team studied genetically modified mice that develop amyloid plaques and normally aging wild-type mice. They examined the animals at six months, when plaques first appeared in the disease model, and at 18 months, when pathology was more advanced. To measure sleep, researchers used devices recording brain electrical activity through EEG and muscle activity through EMG, allowing them to distinguish wakefulness and sleep stages.
In a separate intervention, mice received pexidartinib (PLX3397) in their food for 14 days. The drug blocks a signal microglia rely on to survive; the report says approximately 87% of microglia were depleted. Following this temporary depletion, the mice slept longer and spent more time in deeper sleep stages. The supplied account says the improvement occurred without removing the plaques, although it does not provide full numerical results for each sleep stage or each group.
The researchers interpret the result as evidence that the immune response to plaques may contribute to disrupted sleep, rather than plaques or impaired neurons being the sole explanation. Microglia normally help maintain the brain and respond to damage, but their response to plaques can also involve inflammatory signals. The experiment links microglia depletion with better sleep in mice; it does not, by itself, establish which specific inflammatory signals caused the change.
A Sleep Target Beyond Plaques
Sleep disturbance can add to the burden experienced by people with Alzheimer’s and their families, and it can complicate day-to-day care. This study matters because it suggests that a symptom linked to the disease might be influenced by the brain’s immune response, not only by the plaques associated with Alzheimer’s. If further research supports that mechanism, it could broaden how scientists investigate sleep problems in the disease.
The result is not evidence that removing microglia would be a safe or suitable therapy. These cells have normal protective functions, and the experiment temporarily depleted most of them in mice using a drug intervention. A possible research direction is to understand whether particular inflammatory pathways can be altered while preserving microglia’s beneficial roles. That remains a question for later studies, not a clinical conclusion from this report.
sleep diary journal for tracking sleep patterns
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Tested the Link
Alzheimer’s disease is associated with amyloid plaques, deposits of protein fragments that accumulate between nerve cells. Microglia are specialized immune cells in the brain that respond to threats and help clear debris. The researchers’ account challenges an explanation that sleep loss is mainly a direct consequence of plaque accumulation or neuronal dysfunction: it proposes that the brain’s response to plaques may also disrupt sleep.
To examine the relationship, the team compared a mouse model predisposed to develop plaques with normally aging mice, and used EEG and EMG to measure sleep rather than relying only on observation. Light-sheet microscopy was also used to map plaques and microglia across brain tissue. The mouse model and laboratory measurements provide a way to study biological mechanisms, but they cannot establish that the same intervention would improve sleep in people.
“Basically, we showed that it is not the plaques themselves, or solely dysfunctional neurons, that cause sleep loss but actually microglia.”
— Shannon L. Macauley, associate professor of physiology at the University of Kentucky College of Medicine, as quoted in the ScienceDaily report
wearable sleep tracker with sleep stage monitoring
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Human Effects Remain Unknown
The reported experiments involved mice, not people. The supplied material does not report a human trial, evidence that pexidartinib improves sleep in patients, or whether the same microglia-related mechanism is responsible for sleep disruption in people with Alzheimer’s. It also does not establish the treatment’s safety for this purpose.
Important experimental details are not included in the supplied account, including the exact sleep-duration changes in each group, how long the improvement lasted after the intervention, and whether other biological effects accompanied microglia depletion. The report says plaques remained, but further evidence would be needed to clarify how plaque burden, inflammation and sleep changes relate over time. The findings should not be taken as a recommendation to use pexidartinib for sleep or Alzheimer’s disease.
white noise machine for bedroom sleep
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing the Mechanism Further
The immediate next step is additional research to verify the result and identify which parts of the microglia response are linked to sleep changes. Studies could examine whether targeting specific inflammatory signals can affect sleep while leaving more of microglia’s normal protective activity intact, and whether benefits persist beyond the short intervention described here.
Any move toward clinical use would require evidence in people, including careful evaluation of safety and whether sleep outcomes improve. The supplied report does not announce a human study or give a timetable for one. For now, the finding is a preclinical result that may guide further investigation rather than a proven Alzheimer’s treatment.
Alzheimer's caregiver sleep and dementia care guide
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the researchers find?
In a mouse study, temporarily depleting most microglia was followed by more than two additional hours of sleep per day and more time in deeper sleep stages. The report says this occurred without clearing amyloid plaques.
Were the results demonstrated in people with Alzheimer’s?
No. The reported experiments involved mice with Alzheimer’s-like changes and normally aging mice. The supplied report describes no human trial.
What are microglia?
Microglia are immune cells in the brain that help respond to damage and clear debris. The study suggests their inflammatory response to plaques may contribute to sleep disruption in the mouse model.
Did the intervention remove amyloid plaques?
No. According to the report, sleep improved after most microglia were temporarily depleted without removing the amyloid plaques.
The study does not establish that. It reports a mouse experiment, not evidence of safety or benefit in people, and the findings are not a recommendation to use the drug for Alzheimer’s or sleep problems.
Source: hn
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
